Alice T. Shaw, MD, PhD | Authors


Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLC

June 19, 2017

Alice T. Shaw, MD, PhD, director, thoracic oncology, Massachusetts General Hospital, discusses results of the phase III clinical trial comparing alectinib (Alecensa) versus crizotinib (Xalkori) in first-line treatment for ALK-positive, advanced non–small cell lung cancer.

The Advent of More Potent ALK Inhibitors

January 03, 2014

Alice T. Shaw, MD, PhD, from Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors such as LDK378 and the treatment of ALK-positive lung cancer patients with crizotinib.